Cannabis for Epilepsy UK — Epidyolex, CBD, Medical

Cannabis for Epilepsy in the UK: Medical Access and Treatment Options
The use of cannabis for epilepsy in the UK represents a significant shift in medical thinking about controlled substances and their therapeutic potential. Once considered entirely prohibitive, cannabinoid-based treatments are now available through the NHS, offering hope to patients with severe, treatment-resistant forms of epilepsy. This comprehensive guide explores the current landscape of cannabis epilepsy UK treatment, from approved medications to the legal framework enabling prescriptions.

The Legal Landscape: How Cannabis for Epilepsy Became Possible
Until recently, the idea of prescribing cannabis-derived medicines in the UK seemed impossible. However, a landmark case transformed the regulatory environment entirely. In November 2018, the Home Office granted a special licence to Billy Caldwell, a young boy with severe epilepsy, allowing him to use cannabis oil. This case captured public attention and prompted serious reconsideration of policy.

Shortly after, the Alfie Dingley case became the catalyst for formal legal change. Alfie, who suffered from Dravet syndrome—an extremely severe form of childhood epilepsy—showed remarkable improvement using cannabis oil in the Netherlands. His parents’ campaign for legal access in the UK led to a fundamental shift. In November 2018, the government removed cannabis from Schedule 1, making it theoretically possible for doctors to prescribe cannabis-based medicines.

This regulatory change reflected a growing recognition that cannabis compounds, particularly cannabidiol (CBD) and tetrahydrocannabinol (THC), possess genuine anticonvulsant properties that could benefit patients for whom conventional treatments had failed. The Alfie Dingley case didn’t just change one family’s life—it altered the legal framework for thousands of potential patients across the UK.

Epidyolex: The NHS-Approved CBD Medication

Following the legal changes, the landscape moved swiftly toward formal medical recognition. Epidyolex became the first cannabis-derived medication to receive NHS approval in the United Kingdom, representing the mainstream medical establishment’s acceptance of cannabinoid therapy for specific conditions.

Epidyolex is a pure cannabidiol (CBD) oral solution manufactured by GW Pharmaceuticals. Unlike cannabis products that contain multiple cannabinoids, Epidyolex delivers a precisely measured CBD dose, allowing for controlled medical practice. The medication received approval specifically for treating two severe forms of childhood epilepsy: Dravet syndrome and Lennox-Gastaut syndrome (LGS).

Both conditions are rare, inherited forms of epilepsy characterised by multiple daily seizures that are extremely difficult to manage with conventional antiepileptic drugs. Patients with Dravet syndrome often experience their first seizures in infancy and face significant developmental challenges. Lennox-Gastaut syndrome, typically emerging in early childhood, similarly resists most standard treatments. For families managing these conditions, Epidyolex offers a realistic hope where many other medications have failed.

The NHS approval process for Epidyolex involved rigorous evaluation of clinical trial data demonstrating its efficacy and safety profile. Clinical trials showed that when added to existing treatments, Epidyolex significantly reduced seizure frequency in patients with Dravet and Lennox-Gastaut syndromes. For many patients, the reduction was dramatic—some experiencing seizure reductions exceeding 40 percent.

The Evidence Base for Cannabis in Epilepsy Treatment

The decision to approve cannabis for epilepsy wasn’t based on anecdotal evidence or hope alone. A substantial body of scientific research underpins current clinical practice. Multiple clinical trials, observational studies, and neurological research have established the anticonvulsant properties of cannabidiol and other cannabis compounds.

The mechanism by which CBD works remains not entirely understood, but research suggests it affects multiple neurological pathways involved in seizure generation. Unlike THC, which can sometimes trigger seizures in susceptible individuals, CBD appears to have consistently anti-seizure effects. This distinction is crucial for medical application and patient safety.

The evidence base includes long-term follow-up studies showing sustained benefit from Epidyolex, with patients maintaining seizure reduction over months and years of use. Safety data demonstrates that CBD is generally well-tolerated, with side effects typically being mild and manageable compared to many conventional antiepileptic drugs, which often cause significant cognitive or behavioural problems.

However, important caveats exist. Cannabis-based treatments aren’t suitable for all epilepsy types. Standard epilepsy medications control seizures effectively in approximately 70 percent of patients. Cannabis treatments are primarily relevant for the remaining 30 percent with drug-resistant epilepsy. Evidence remains limited for cannabis use in adult epilepsy and in conditions other than Dravet and Lennox-Gastaut syndromes, though research is ongoing.

Medical Cannabis Prescriptions for Epilepsy Beyond Epidyolex

Whilst Epidyolex represents the most straightforward NHS access route, specialists can also prescribe bespoke medical cannabis products for epilepsy in carefully controlled circumstances. This represents a more complex pathway than Epidyolex, as such prescriptions fall under the specialist licence route rather than standard NHS approval.

Private specialists registered with the General Medical Council can legally prescribe medical cannabis products, including whole-plant extracts with varying CBD and THC ratios. Some epilepsy patients access these services privately, though costs are substantial—often £1,000 to £2,000 monthly—and currently the NHS does not routinely fund these products outside of Epidyolex.

Cannabis-based products for medical use (CBPMs) prescribable by specialists include oils, tinctures, and capsules containing standardised amounts of cannabinoids. The rationale for considering products beyond pure CBD relates to evidence suggesting that whole-plant extracts may offer additional benefits through the “entourage effect,” where multiple cannabinoids work synergistically.

Accessing Cannabis for Epilepsy on the NHS: The Pathway to Prescription

Obtaining Epidyolex through the NHS requires navigating a specific clinical pathway. First, patients must be under the care of a specialist neurologist or paediatrician experienced in treating epilepsy. For children with Dravet or Lennox-Gastaut syndrome who meet diagnostic criteria, clinicians can initiate discussions about Epidyolex as an add-on therapy when previous treatments have inadequately controlled seizures.

The prescribing neurologist must confirm the diagnosis through appropriate genetic testing and EEG recordings. They must also document that the patient has tried at least two appropriate conventional antiepileptic drugs without achieving adequate seizure control. This demonstrates that cannabis represents a genuine last resort rather than a first-line option.

Once established on Epidyolex, patients require regular monitoring through specialist clinics to assess efficacy and safety. Blood tests check liver function, as CBD can occasionally affect hepatic metabolism. Seizure diaries document any improvements or emerging concerns. This structured approach ensures medical oversight and allows for adjustments if needed.

For those seeking private cannabis-based prescriptions beyond Epidyolex, patients contact private clinics offering specialist cannabis medicine services. The consultant reviews medical history, confirms treatment-resistant status, and if appropriate, issues a private prescription. Costs typically exceed NHS capacity, explaining why private access remains a privilege for affluent families.

Challenges and Future Directions

Despite legal changes and NHS approval for Epidyolex, challenges persist. Some clinicians remain cautious about cannabis-based treatments due to historical stigma and limited familiarity with cannabinoid pharmacology. Training and education for healthcare professionals continues to develop but remains inconsistent across NHS services.

Access disparities exist geographically, with some regions offering more progressive specialist cannabis services than others. Patients in some areas struggle to find neurologists willing to prescribe or discuss Epidyolex, whilst others encounter enthusiastic specialists. This inconsistency represents an equity problem within the NHS.

Research continues into cannabis efficacy for broader epilepsy populations. Ongoing trials investigate whether Epidyolex or other cannabis products might benefit adults with epilepsy or children with other seizure disorders. Such expansion could eventually widen access beyond current approved indications, though each expansion requires rigorous evidence generation.

Conclusion

Cannabis for epilepsy in the UK has transformed from prohibition to mainstream medical treatment within five years—a remarkable regulatory shift driven by patient advocacy and scientific evidence. Epidyolex now provides NHS-approved access to precise CBD therapy for severe childhood epilepsy, whilst specialist-prescribed cannabis products offer additional options outside standard NHS commissioning.

The journey from the Alfie Dingley case to current practice demonstrates how compelling patient stories, combined with robust research evidence, can reshape healthcare policy. Families managing Dravet or Lennox-Gastaut syndrome now have legitimate, legally protected treatment options previously unavailable. As research evolves and clinical experience accumulates, the role of cannabis in epilepsy management will likely expand further, potentially benefiting increasing numbers of patients for whom conventional treatments have failed.

Clinical Evidence and NICE Guidance

Evidence Level: Strong (for Epidyolex/Dravet/LGS) — Limited (for other epilepsies)

NICE Guideline NG144 (Cannabis-based medicinal products, November 2019) specifically recommends Epidyolex (cannabidiol oral solution) within NHS commissioning for patients aged 2 years and over with seizures associated with Dravet syndrome or Lennox-Gastaut syndrome (LGS), used as adjunctive therapy with clobazam.

Phase 3 RCTs (GWPCARE1–6) demonstrated that Epidyolex reduced convulsive seizure frequency by approximately 39–44% compared to placebo in Dravet syndrome patients, and drop-seizure frequency by 37–44% in LGS patients. These are the only cannabis-derived products with Level 1 evidence (RCT data) supporting NHS prescribing for epilepsy. For other cannabis products and other epilepsy types, evidence remains limited and prescribing is off-label.

NICE does not currently recommend other CBMPs (e.g. unlicensed CBD oils, THC-containing products) for epilepsy outside of specialist clinical trial settings. Nabiximols (Sativex) is not licensed for epilepsy in the UK.

Contraindications

Hypersensitivity to cannabidiol or any Epidyolex excipient (sesame oil, ethanol) — absolute contraindication
Severe hepatic impairment — Epidyolex is contraindicated; CBD is extensively hepatically metabolised; dose reduction required in mild-moderate impairment (Child-Pugh A/B)
Pregnancy — insufficient safety data for Epidyolex in pregnancy; potential foetal harm cannot be excluded; use only if clearly necessary with specialist obstetric input
Breastfeeding — CBD is excreted in breast milk; breastfeeding should be discontinued during treatment
Under 2 years — Epidyolex is not licensed for children under 2 years of age
Concomitant high-dose valproate without LFT monitoring — combination markedly increases hepatotoxicity risk; baseline and regular LFTs mandatory

Drug Interactions

Epilepsy patients are almost universally on antiepileptic drugs (AEDs); interactions with Epidyolex are clinically critical:

Clobazam — most important interaction; CBD markedly increases plasma levels of N-desmethylclobazam (active metabolite) via CYP2C19 inhibition; sedation increases significantly; clobazam dose reduction of 25–50% is typically required when initiating Epidyolex
Valproate (sodium valproate / valproic acid) — both Epidyolex and valproate are hepatotoxic; combination requires baseline LFTs, and monitoring at 1, 3, and 6 months; avoid if LFTs are already elevated
Stiripentol — used in Dravet syndrome; inhibits CYP3A4 and CYP2C19; increases CBD plasma levels; dose adjustment may be needed
Rufinamide — CBD reduces rufinamide levels by approximately 16%; monitor seizure control
Topiramate — additive pharmacodynamic interaction; increased somnolence and appetite loss
Lamotrigine — CBD may increase lamotrigine levels via UGT inhibition; monitor for lamotrigine toxicity (dizziness, diplopia)
Everolimus / sirolimus — CYP3A4 inhibition by CBD increases immunosuppressant levels; relevant in tuberous sclerosis complex patients
Warfarin — CBD inhibits CYP2C9; INR elevation; monitor closely

Dosing Guidance (Epidyolex)

Starting dose: 2.5 mg/kg twice daily (5 mg/kg/day total)
Titration: increase by 2.5 mg/kg twice daily weekly, based on response and tolerability
Maximum dose: 10 mg/kg twice daily (20 mg/kg/day) — though clinical trials showed highest efficacy at 10–20 mg/kg/day
Administration: oral solution (100 mg/mL); take with food to improve tolerability and reduce nausea
LFT monitoring: at baseline, 1 month, 3 months, 6 months, then annually; if ALT/AST exceeds 3x upper limit of normal, reduce dose or discontinue
Clobazam adjustment: anticipate need for 25–50% clobazam dose reduction when adding Epidyolex

Side Effects

Common: somnolence (very common, especially with clobazam), decreased appetite, diarrhoea, pyrexia, fatigue, vomiting, upper respiratory tract infections
Hepatotoxicity: transaminase elevations in 12–13% of patients in trials; severe hepatic injury reported; monitor LFTs; risk increased by valproate co-prescription
Weight loss: decreased appetite and weight loss occur particularly in children; monitor growth parameters
Rash: more common with concurrent valproate use
Suicidal ideation: as with all AEDs, monitor for mood changes, depression, and suicidal ideation per MHRA warning
Withdrawal: do not stop abruptly; taper over at least 4 weeks to reduce seizure risk

When Medical Cannabis Is NOT Appropriate for Epilepsy

Epilepsy type other than Dravet syndrome or Lennox-Gastaut syndrome seeking NHS-funded Epidyolex — NICE does not recommend routine prescribing for other epilepsy types
Child under 2 years of age
Severe hepatic impairment
Uncontrolled or inadequately characterised seizure disorder without specialist paediatric neurology or adult neurology input
Patient or parent/carer unwilling to comply with mandatory liver function monitoring
Seeking non-pharmaceutical CBD oils or THC products as seizure treatment — these are not licensed, not recommended by NICE, and may interact unpredictably with AEDs

Note on NHS availability: Epidyolex is the one cannabis-derived product that IS available on the NHS — but only for Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 and over, prescribed by a specialist neurologist. All other cannabis products for epilepsy are available only via private specialist prescription and are not commissioned by NHS England.

Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before starting any new treatment.

Cannabis for Epilepsy UK — Epidyolex, CBD, Medical Guide